Stock MRCK MERCK KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Merck KGaA Wiener Boerse

Equities

MRCK

DE0006599905

Pharmaceuticals

End-of-day quote Wiener Boerse
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
152.2 EUR +1.03% Intraday chart for Merck KGaA -0.07% +6.47%
May. 03 MERCK KGAA : JP Morgan maintains a Buy rating ZD
May. 01 MERCK KGAA : Jefferies keeps its Buy rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,804 61,021 98,695 78,651 62,651 66,086 - -
Enterprise Value (EV) 1 58,160 71,683 107,596 86,979 62,651 72,806 70,987 68,584
P/E ratio 34.7 x 30.7 x 32.3 x 23.6 x 22.2 x 22.3 x 18.9 x 16.9 x
Yield 1.23% 1% 0.81% 1.22% - 1.51% 1.6% 1.66%
Capitalization / Revenue 2.84 x 3.48 x 5.01 x 3.54 x 2.98 x 3.11 x 2.93 x 2.79 x
EV / Revenue 3.6 x 4.09 x 5.47 x 3.91 x 2.98 x 3.43 x 3.15 x 2.9 x
EV / EBITDA 13.3 x 13.8 x 17.6 x 12.7 x 10.7 x 12.5 x 10.8 x 9.65 x
EV / FCF 28.5 x 34.7 x 30.3 x 31.9 x - 27.7 x 23.7 x 20.2 x
FCF Yield 3.51% 2.88% 3.3% 3.14% - 3.61% 4.22% 4.95%
Price to Book 2.56 x 3.59 x 4.63 x 3.03 x - 2.29 x 2.1 x 1.94 x
Nbr of stocks (in thousands) 434,778 434,778 434,778 434,778 434,778 434,778 - -
Reference price 2 105.4 140.4 227.0 180.9 144.1 152.0 152.0 152.0
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,152 17,534 19,687 22,232 20,993 21,257 22,522 23,682
EBITDA 1 4,385 5,201 6,103 6,849 5,879 5,835 6,572 7,104
EBIT 1 2,120 2,985 4,179 4,474 3,609 3,847 4,512 5,019
Operating Margin 13.13% 17.02% 21.23% 20.12% 17.19% 18.1% 20.03% 21.19%
Earnings before Tax (EBT) 1 1,735 2,630 3,924 4,287 3,484 3,751 4,432 4,945
Net income 1 1,320 1,987 3,055 3,326 2,824 2,956 3,488 3,896
Net margin 8.17% 11.33% 15.52% 14.96% 13.45% 13.9% 15.49% 16.45%
EPS 2 3.040 4.570 7.030 7.650 6.490 6.828 8.058 8.975
Free Cash Flow 1 2,043 2,065 3,550 2,728 - 2,629 2,996 3,392
FCF margin 12.65% 11.78% 18.03% 12.27% - 12.37% 13.3% 14.32%
FCF Conversion (EBITDA) 46.6% 39.7% 58.17% 39.83% - 45.07% 45.59% 47.75%
FCF Conversion (Net income) 154.77% 103.9% 116.22% 82.02% - 88.97% 85.9% 87.06%
Dividend per Share 2 1.300 1.400 1.850 2.200 - 2.299 2.426 2.518
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 8,489 4,973 5,213 5,198 5,568 5,806 5,660 5,293 5,302 5,173 5,225 5,122 5,240 5,355 5,485 -
EBITDA 1 2,256 1,552 1,464 1,629 1,782 1,810 1,628 1,587 1,553 1,446 1,293 1,334 1,408 1,485 1,693 -
EBIT 1 - 1,047 1,039 1,173 1,177 1,234 889.6 1,035 969 983 621 815.2 807.2 1,068 1,129 -
Operating Margin - 21.05% 19.93% 22.57% 21.14% 21.26% 15.72% 19.55% 18.28% 19% 11.89% 15.91% 15.41% 19.94% 20.59% -
Earnings before Tax (EBT) 1 - 993 991.9 1,139 1,122 1,187 839.1 1,012 894 937 641 784.8 782.1 1,043 1,097 -
Net income 1 - 761 802.1 880.4 867.1 923.2 655 796 704 739 586 657.3 703.3 819.9 851.2 -
Net margin - 15.3% 15.39% 16.94% 15.57% 15.9% 11.57% 15.04% 13.28% 14.29% 11.22% 12.83% 13.42% 15.31% 15.52% -
EPS 2 1.720 1.750 1.840 2.020 1.990 2.120 1.510 1.830 1.620 1.700 1.340 1.524 1.619 1.897 1.970 -
Dividend per Share 2 - - 1.850 - - - 2.200 - - - - 0.5500 0.5500 0.5500 0.5500 0.6000
Announcement Date 8/6/20 11/11/21 3/3/22 5/12/22 8/4/22 11/10/22 3/2/23 5/11/23 8/3/23 11/9/23 3/7/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,357 10,662 8,902 8,328 - 6,720 4,901 2,498
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.818 x 2.05 x 1.459 x 1.216 x - 1.152 x 0.7457 x 0.3516 x
Free Cash Flow 1 2,043 2,065 3,550 2,728 - 2,629 2,996 3,392
ROE (net income / shareholders' equity) 13.8% 16.7% 19.8% 18.5% - 13% 13.9% 14.1%
ROA (Net income/ Total Assets) 3.27% 4.64% 8.7% 9.31% - 6.51% 7.36% 7.72%
Assets 1 40,348 42,804 35,111 35,718 - 45,374 47,376 50,456
Book Value Per Share 2 41.10 39.10 49.10 59.60 - 66.30 72.30 78.40
Cash Flow per Share 2 6.580 8.000 10.60 9.800 - 10.70 11.40 12.50
Capex 1 813 1,413 1,066 1,531 - 1,947 1,983 1,988
Capex / Sales 5.03% 8.06% 5.41% 6.89% - 9.16% 8.81% 8.4%
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Merck KGaA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
152 EUR
Average target price
182 EUR
Spread / Average Target
+19.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.3B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.75% 5.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B
YUHAN CORPORATION Stock Yuhan Corporation
+4.51% 3.96B
INDIVIOR PLC Stock Indivior PLC
+21.10% 2.44B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+6.53% 1.69B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. MRCK Stock
  5. Financials Merck KGaA